首页 > 最新文献

Journal of Pharmaceutical Innovation最新文献

英文 中文
Unveiling the Pharmacological Mechanism of Cosmos Caudatus Compounds as Lung Cancer Drug Candidates: Pharmacology Networking, Molecular Docking, and Experimental Validation
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-21 DOI: 10.1007/s12247-025-09989-0
Abdul Halim Umar, Citra Surya Ningsi Biringallo, Pratiwi Intan Tuyuwale, Anita Kila, Karin Dian Febyola, Reny Syahruni, Wahyu Hendrarti, Mohamad Rafi, Diah Ratnadewi

Cosmos caudatus is a traditional Indonesian medicinal plant commonly used in the treatment of cancer, hypertension, diabetes, osteoporosis, and other potential health conditions. However, the mechanisms behind its compounds, targets, diseases, disease pathways, and their molecular profiles in treating lung cancer remain unclear. Therefore, a comprehensive approach is required to study these mechanisms by integrating metabolomics, bioinformatics, and in vitro experimental validation to explore the active compounds, targets, diseases, disease pathways, and molecular mechanisms involved in the treatment of lung cancer. The active compounds were identified through analysis using ultrahigh-performance liquid chromatography-quadrupole-orbital ion trap-high resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS), and the screening of active compounds was conducted based on ADMET parameters. Potential compounds from C. caudatus and lung cancer-related targets were retrieved from public databases, such as SwissTargetPrediction, DisGeNET, DrugBank, GeneCards, PharmGKB, and TTD. Gene Ontology (GO) analysis of the targets was performed using DAVID, and protein–protein interactions (PPI) were analyzed using STRING and Cytoscape. A pharmacological network was constructed with Cytoscape. Finally, molecular docking analysis was conducted to predict and validate the interactions between C. caudatus compounds and core lung cancer targets. The metabolomic approach identified 66 compounds in the leaves, of which 13 met the criteria for gastrointestinal drugs. The compounds 3’,4’,5,7-tetrahydroxyflavone, AKT1 target, lung neoplasms diseases, and PIP3 activating AKT signalling pathway, became the core target with the highest degree value in the pharmacological network formed. In the protein-protein interaction (PPI) network, AKT1 again became the core target with the highest degree value. Gene Ontology (GO) functional enrichment analysis revealed that the biological processes, molecular functions, cellular components, and KEGG pathways in lung cancer were phosphorylation, cytoplasm, protein binding, and cancer pathways, respectively. The three compounds with the best binding energy and hydrogen bonding were 3’,4’,5,7-tetrahydroxyflavone-AKT1 (9C1W), gamma-mangostin-EGFR (3P0V), and cratoxyarborenone E-TNF (1XU1), with binding energies of − 10.8, − 8.9, and − 9.6 kcal/mol, respectively. The methanol extracts inhibited A549 cells at a concentration of 156.12 µg/mL. The combination of these methods provides insights into the pharmacological mechanisms of C. caudatus compounds in the treatment of lung cancer.

{"title":"Unveiling the Pharmacological Mechanism of Cosmos Caudatus Compounds as Lung Cancer Drug Candidates: Pharmacology Networking, Molecular Docking, and Experimental Validation","authors":"Abdul Halim Umar,&nbsp;Citra Surya Ningsi Biringallo,&nbsp;Pratiwi Intan Tuyuwale,&nbsp;Anita Kila,&nbsp;Karin Dian Febyola,&nbsp;Reny Syahruni,&nbsp;Wahyu Hendrarti,&nbsp;Mohamad Rafi,&nbsp;Diah Ratnadewi","doi":"10.1007/s12247-025-09989-0","DOIUrl":"10.1007/s12247-025-09989-0","url":null,"abstract":"<div><p><i>Cosmos caudatus</i> is a traditional Indonesian medicinal plant commonly used in the treatment of cancer, hypertension, diabetes, osteoporosis, and other potential health conditions. However, the mechanisms behind its compounds, targets, diseases, disease pathways, and their molecular profiles in treating lung cancer remain unclear. Therefore, a comprehensive approach is required to study these mechanisms by integrating metabolomics, bioinformatics, and in vitro experimental validation to explore the active compounds, targets, diseases, disease pathways, and molecular mechanisms involved in the treatment of lung cancer. The active compounds were identified through analysis using ultrahigh-performance liquid chromatography-quadrupole-orbital ion trap-high resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS), and the screening of active compounds was conducted based on ADMET parameters. Potential compounds from <i>C. caudatus</i> and lung cancer-related targets were retrieved from public databases, such as SwissTargetPrediction, DisGeNET, DrugBank, GeneCards, PharmGKB, and TTD. Gene Ontology (GO) analysis of the targets was performed using DAVID, and protein–protein interactions (PPI) were analyzed using STRING and Cytoscape. A pharmacological network was constructed with Cytoscape. Finally, molecular docking analysis was conducted to predict and validate the interactions between <i>C. caudatus</i> compounds and core lung cancer targets. The metabolomic approach identified 66 compounds in the leaves, of which 13 met the criteria for gastrointestinal drugs. The compounds 3’,4’,5,7-tetrahydroxyflavone, AKT1 target, lung neoplasms diseases, and PIP3 activating AKT signalling pathway, became the core target with the highest degree value in the pharmacological network formed. In the protein-protein interaction (PPI) network, AKT1 again became the core target with the highest degree value. Gene Ontology (GO) functional enrichment analysis revealed that the biological processes, molecular functions, cellular components, and KEGG pathways in lung cancer were phosphorylation, cytoplasm, protein binding, and cancer pathways, respectively. The three compounds with the best binding energy and hydrogen bonding were 3’,4’,5,7-tetrahydroxyflavone-AKT1 (9C1W), gamma-mangostin-EGFR (3P0V), and cratoxyarborenone E-TNF (1XU1), with binding energies of − 10.8, − 8.9, and − 9.6 kcal/mol, respectively. The methanol extracts inhibited A549 cells at a concentration of 156.12 µg/mL. The combination of these methods provides insights into the pharmacological mechanisms of <i>C. caudatus</i> compounds in the treatment of lung cancer.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Dabigatran Etexilate Self-Micro-Emulsifying Drug Delivery Systems Formulation Optimization Techniques: Design Expert Vs. MATLAB
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-21 DOI: 10.1007/s12247-025-09990-7
Rama Devi Korni, Majji Akhil, Bora Thanmaisree, Jagadeesh Panda, Killana Sre Meghna

Background

This work aimed to formulate Dabigatran etexilate, a BCS class II medication, as self-micro-emulsifying drug delivery system (SMEDDS) to increase its rate of dissolution. By doing solubility experiments of the medication in various oils, surfactants, and cosurfactants, the three primary formulation components of a SMEDDS formulation were chosen. Formulation design and optimization were done by Box-Behnken design in Design Expert software. A comparative study was conducted with artificial neural networks (ANN) using MATLAB Software for better prediction of the selected output variables. The formulations were made and tested for transmittance and drug release percentages. The desirability function was used to create an optimal formulation, which was then made and tested for emulsification time, centrifugation, viscosity, cloud point, dilution and phase separation. Neusilin was used as an adsorbent to further solidify the optimized formulation and produce a stable product. The solidified optimized formulation was then subjected to fourier transform infrared spectroscopy and x-ray diffraction studies.

Results

The optimized SMEDDS Dabigatran etexilate formulations contained mixtures of Kollisolv MCT70 (oil), Kolliphor EL (surfactant), and PEG 400 (cosurfactant). The higher R2 values and lower MSE values of percentage drug release and percentage transmittance for ANN compared to Box-Behnken design-based quadratic model indicate better predictability of ANN. In vitro release of optimized SMEDDS was 81.09 ± 1.37% within 1 h. It exhibited a significant transmittance of 89 ± 0.63%.

Conclusion

The results indicated that SMEDDS capsules could be effectively used to improve the solubility rate of Dabigatran etexilate. ANN can be successfully used as a better model for predicting characteristics of formulations.

Graphical Abstract

{"title":"Comparison of Dabigatran Etexilate Self-Micro-Emulsifying Drug Delivery Systems Formulation Optimization Techniques: Design Expert Vs. MATLAB","authors":"Rama Devi Korni,&nbsp;Majji Akhil,&nbsp;Bora Thanmaisree,&nbsp;Jagadeesh Panda,&nbsp;Killana Sre Meghna","doi":"10.1007/s12247-025-09990-7","DOIUrl":"10.1007/s12247-025-09990-7","url":null,"abstract":"<div><h3>Background</h3><p>This work aimed to formulate Dabigatran etexilate, a BCS class II medication, as self-micro-emulsifying drug delivery system (SMEDDS) to increase its rate of dissolution. By doing solubility experiments of the medication in various oils, surfactants, and cosurfactants, the three primary formulation components of a SMEDDS formulation were chosen. Formulation design and optimization were done by Box-Behnken design in Design Expert software. A comparative study was conducted with artificial neural networks (ANN) using MATLAB Software for better prediction of the selected output variables. The formulations were made and tested for transmittance and drug release percentages. The desirability function was used to create an optimal formulation, which was then made and tested for emulsification time, centrifugation, viscosity, cloud point, dilution and phase separation. Neusilin was used as an adsorbent to further solidify the optimized formulation and produce a stable product. The solidified optimized formulation was then subjected to fourier transform infrared spectroscopy and x-ray diffraction studies.</p><h3>Results</h3><p>The optimized SMEDDS Dabigatran etexilate formulations contained mixtures of Kollisolv MCT70 (oil), Kolliphor EL (surfactant), and PEG 400 (cosurfactant). The higher R<sup>2</sup> values and lower MSE values of percentage drug release and percentage transmittance for ANN compared to Box-Behnken design-based quadratic model indicate better predictability of ANN. In vitro release of optimized SMEDDS was 81.09 ± 1.37% within 1 h. It exhibited a significant transmittance of 89 ± 0.63%.</p><h3>Conclusion</h3><p>The results indicated that SMEDDS capsules could be effectively used to improve the solubility rate of Dabigatran etexilate. ANN can be successfully used as a better model for predicting characteristics of formulations.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective Hepatoprotective Actions of Novel Nano-formulations of Sildenafil and Neem Extract in Counteracting Oral Carbon Tetrachloride-induced Liver Injury in Rats
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-15 DOI: 10.1007/s12247-025-09972-9
Mahmoud S. Sabra, Essmat A. H. Allam, Madeha H. A. Darwish, Al-Hassan Mohammed Mostafa, Abeer S. Hassan, Marwa G. Gamea, Dalia Hassan, Mohamed M. Elbadr

Purpose

A multitude of inflammatory cells and chemical mediators initiate a complex cascade that ultimately leads to hepatocyte death and a systemic inflammatory response. This research aimed to investigate the potential effects of sildenafil and neem (Azadirachta indica) extract, in both conventional and nanoparticle (NP) forms, in the treatment of moderate acute liver damage induced by orogastric carbon tetrachloride (CCL4).

Methods

To induce moderate acute hepatic damage a single oral dosage of CCL4 (2.5 mL/kg body weight) was provided 24 h before euthanasia. In liver damage-induced CCL4, sildenafil and neem extract were given in conventional and nanoparticle (PLGA or niosome) forms. To find histological anomalies and hepatic changes, behavioral, biochemical, histopathological, and immunohistochemical methods were used.

Results

The findings indicated that sildenafil and/or neem extract, especially in NP combination, significantly mitigated CCL4-induced acute moderate liver damage. Indicators of liver function, including aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT), albumin, bilirubin and gamma-glutamyl transferase (GGT), shown improvement, particularly with the nanoparticulation of both therapies. Treatment, particularly in NP forms, improved the levels of malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase activity (GPx) in liver tissues. A significant reduction in NF-κB expression in hepatic tissue was shown in treatment groups. Also, medication resulted in lower levels of interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), caspase-3, and transforming growth factor-beta (TGF-β) in the liver tissue homogenates. Liver function was more significantly improved by the drug-NP combination.

Conclusions

This study verified the beneficial therapeutic effects of the combination of sildenafil and neem extract, particularly in NP forms, using biochemical, histological, and immunohistochemical analyses in a rat model of liver damage.

{"title":"Prospective Hepatoprotective Actions of Novel Nano-formulations of Sildenafil and Neem Extract in Counteracting Oral Carbon Tetrachloride-induced Liver Injury in Rats","authors":"Mahmoud S. Sabra,&nbsp;Essmat A. H. Allam,&nbsp;Madeha H. A. Darwish,&nbsp;Al-Hassan Mohammed Mostafa,&nbsp;Abeer S. Hassan,&nbsp;Marwa G. Gamea,&nbsp;Dalia Hassan,&nbsp;Mohamed M. Elbadr","doi":"10.1007/s12247-025-09972-9","DOIUrl":"10.1007/s12247-025-09972-9","url":null,"abstract":"<div><h3>Purpose</h3><p>A multitude of inflammatory cells and chemical mediators initiate a complex cascade that ultimately leads to hepatocyte death and a systemic inflammatory response. This research aimed to investigate the potential effects of sildenafil and neem (Azadirachta indica) extract, in both conventional and nanoparticle (NP) forms, in the treatment of moderate acute liver damage induced by orogastric carbon tetrachloride (CCL<sub>4</sub>).</p><h3>Methods</h3><p>To induce moderate acute hepatic damage a single oral dosage of CCL<sub>4</sub> (2.5 mL/kg body weight) was provided 24 h before euthanasia. In liver damage-induced CCL<sub>4</sub>, sildenafil and neem extract were given in conventional and nanoparticle (PLGA or niosome) forms. To find histological anomalies and hepatic changes, behavioral, biochemical, histopathological, and immunohistochemical methods were used.</p><h3>Results</h3><p>The findings indicated that sildenafil and/or neem extract, especially in NP combination, significantly mitigated CCL<sub>4</sub>-induced acute moderate liver damage. Indicators of liver function, including aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT), albumin, bilirubin and gamma-glutamyl transferase (GGT), shown improvement, particularly with the nanoparticulation of both therapies. Treatment, particularly in NP forms, improved the levels of malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase activity (GPx) in liver tissues. A significant reduction in NF-κB expression in hepatic tissue was shown in treatment groups. Also, medication resulted in lower levels of interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), caspase-3, and transforming growth factor-beta (TGF-β) in the liver tissue homogenates. Liver function was more significantly improved by the drug-NP combination.</p><h3>Conclusions</h3><p>This study verified the beneficial therapeutic effects of the combination of sildenafil and neem extract, particularly in NP forms, using biochemical, histological, and immunohistochemical analyses in a rat model of liver damage.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12247-025-09972-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143830811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing of Staphylococcus aureus Bacterial Ghosts Loaded with Docetaxel Nanoparticles for Treatment of Breast Cancer 利用装载多西他赛纳米粒子的金黄色葡萄球菌细菌幽灵治疗乳腺癌
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-14 DOI: 10.1007/s12247-025-09965-8
Mounir M. Bekhit, Mohammed M. Almutairi, Mohamed Ibrahim, Sami A. Alzahrani, Mohamed M. Badran, Riyad F. Alzhrani, Mohamed H. M. Al-Agamy, Khalid Alyahya, Fadilah Sfouq Aleanizy, Fars K. Alanazi

Purpose

Bacterial ghosts (BGs) are the bacterial shells of Gram-positive and Gram-negative bacteria devoid of internal contents. This study aimed to utilize S. aureus BGs loaded with pre-prepared nanoparticles (NPs) of DTX as a novel delivery system targeting BC with minimal toxicity. A novel protocol for S. aureus ghost preparation using 7% v/v tween 80 and formic acid was developed.

Methods

The ghosts were characterized by SEM, and protein and DNA release were analyzed spectrophotometrically and via gel electrophoresis. DTX nanoparticles (NPs) were fabricated using antisolvent precipitation, optimized for particle size, zeta potential, and physicochemical properties. The antiproliferative activity of DTX-loaded S. aureus ghosts on breast cancer cells were assessed. In vitro release studies and mathematical release kinetics of DTX from the ghosts were evaluated, along with their cytotoxic activity in MDA-MB-231 cells.

Results

Findings revealed that the S. aureus ghosts were successfully produced by employing our proposed protocol. All tests confirm that the produced ghosts are free of internal and genetic content. The results showed a maximum loading capacity of 37.3 ± 0.8% with a maximum entrapment efficiency of 75.5 ± 0.8%. According to the in vitro release studies conducted on DTX-loaded ghosts over 16 days, there was an initial burst release rate of 53.3% in the first six hours, followed by a sustained release that continued for the entire 16-day period, reaching a maximum release rate of 69.2%. Mathematical analysis of the release kinetics of DTX from S. aureus ghosts indicated that it followed the Higuchi model, suggesting a diffusion process. The application of the Krosmeyer-Peppas model revealed an n value of 0.9473, indicating that the release was non-Fickian or anomalous. The assay of the antiproliferative activity of the prepared loaded S. aureus ghosts by the chemotherapy NPs on the BC cell line was relatively safe with no cytotoxicity. S. aureus BGs loaded with DTX-NPs show sustained release and significant antiproliferative activity against BC cells presenting a promising drug delivery system.

Conclusion

Our study highlights several benefits, such as improved stability and sustained release, which could enhance therapeutic outcomes. The BG-loaded drug approach offers a promising therapeutic strategy for delivering drugs to the targeted tissues for cancer treatment.

{"title":"Harnessing of Staphylococcus aureus Bacterial Ghosts Loaded with Docetaxel Nanoparticles for Treatment of Breast Cancer","authors":"Mounir M. Bekhit,&nbsp;Mohammed M. Almutairi,&nbsp;Mohamed Ibrahim,&nbsp;Sami A. Alzahrani,&nbsp;Mohamed M. Badran,&nbsp;Riyad F. Alzhrani,&nbsp;Mohamed H. M. Al-Agamy,&nbsp;Khalid Alyahya,&nbsp;Fadilah Sfouq Aleanizy,&nbsp;Fars K. Alanazi","doi":"10.1007/s12247-025-09965-8","DOIUrl":"10.1007/s12247-025-09965-8","url":null,"abstract":"<div><h3>Purpose</h3><p>Bacterial ghosts (BGs) are the bacterial shells of Gram-positive and Gram-negative bacteria devoid of internal contents. This study aimed to utilize S. aureus BGs loaded with pre-prepared nanoparticles (NPs) of DTX as a novel delivery system targeting BC with minimal toxicity. A novel protocol for S. aureus ghost preparation using 7% v/v tween 80 and formic acid was developed.</p><h3>Methods</h3><p>The ghosts were characterized by SEM, and protein and DNA release were analyzed spectrophotometrically and via gel electrophoresis. DTX nanoparticles (NPs) were fabricated using antisolvent precipitation, optimized for particle size, zeta potential, and physicochemical properties. The antiproliferative activity of DTX-loaded S. aureus ghosts on breast cancer cells were assessed. In vitro release studies and mathematical release kinetics of DTX from the ghosts were evaluated, along with their cytotoxic activity in MDA-MB-231 cells.</p><h3>Results</h3><p>Findings revealed that the S. aureus ghosts were successfully produced by employing our proposed protocol. All tests confirm that the produced ghosts are free of internal and genetic content. The results showed a maximum loading capacity of 37.3 ± 0.8% with a maximum entrapment efficiency of 75.5 ± 0.8%. According to the in vitro release studies conducted on DTX-loaded ghosts over 16 days, there was an initial burst release rate of 53.3% in the first six hours, followed by a sustained release that continued for the entire 16-day period, reaching a maximum release rate of 69.2%. Mathematical analysis of the release kinetics of DTX from S. aureus ghosts indicated that it followed the Higuchi model, suggesting a diffusion process. The application of the Krosmeyer-Peppas model revealed an n value of 0.9473, indicating that the release was non-Fickian or anomalous. The assay of the antiproliferative activity of the prepared loaded S. aureus ghosts by the chemotherapy NPs on the BC cell line was relatively safe with no cytotoxicity. S. aureus BGs loaded with DTX-NPs show sustained release and significant antiproliferative activity against BC cells presenting a promising drug delivery system.</p><h3>Conclusion</h3><p>Our study highlights several benefits, such as improved stability and sustained release, which could enhance therapeutic outcomes. The BG-loaded drug approach offers a promising therapeutic strategy for delivering drugs to the targeted tissues for cancer treatment.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhanced Delivery of Posaconazole Using Novel Solid Self Nanoemulsifying Drug Delivery System: In Vitro Characterization and Pharmacokinetic Study in Wistar Rats 利用新型固体自纳米乳化给药系统提高泊沙康唑的给药效率:Wistar 大鼠的体外表征和药代动力学研究
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-14 DOI: 10.1007/s12247-025-09985-4
Hardikkumar K. Patel, Naitikkumar D. Trivedi, Vaishali T. Thakkar, Alpesh D. Patel, Upama N. Trivedi, Devesh U. Kapoor

Purpose

Posaconazole (POS) is widely used as an antifungal agent effective against Candida infections. Because of its very low water and high fat solubility, it falls under the Biopharmaceutics Classification System (BCS) Class II. It showed considerable differences in absorption rates among individuals when administered orally. To overcome these obstacles, the current research concentrates on creating a solid self nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of POS to enhance its dissolution rate and bioavailability.

Methods

The choice of formulation components, Capmul MCM C8 as an oil, Tween 20 as a surfactant, and Acrysol K140 as a co-surfactant depended on their ability to solubilize POS and their capacity to form emulsions. Ternary phase diagrams were drawn to pinpoint and delineate the micro-emulsification region. The D-optimal mixture design was employed to facilitate the selection of the most optimized formulation by evaluating vital product characteristics including globule size, zeta potential, transparency percentage as well as emulsification efficiency. The optimized liquid SNEDDS (L-SNEDDS) was then converted into a solid state by employing Neusilin® US2 as a porous carrier, improving the product’s stability and handling ease. The prepared formulation was further evaluated by in vitro and in vivo study.

Results

Examination of the S-SNEDDS structure through scanning electron microscopy showed spherical, granular particles, suggesting favourable flow characteristics. Dissolution tests conducted in vitro revealed that the rate of POS release from the S-SNEDDS was superior to that of unprocessed drug and marketed formulation. In vivo bioavailability study showed 2.27 and 1.96 fold higher bioavailability as compared to pure drug and marketed formulation respectively.

Conclusion

Present study revealed that the ability to self-emulsify was preserved when the L-SNEDDS was solidified. Further it demonstrated enhancement in dissolution and bioavailability of POS which depicted use of developed POS loaded S-SNEDDS for successful oral administration.

{"title":"Enhanced Delivery of Posaconazole Using Novel Solid Self Nanoemulsifying Drug Delivery System: In Vitro Characterization and Pharmacokinetic Study in Wistar Rats","authors":"Hardikkumar K. Patel,&nbsp;Naitikkumar D. Trivedi,&nbsp;Vaishali T. Thakkar,&nbsp;Alpesh D. Patel,&nbsp;Upama N. Trivedi,&nbsp;Devesh U. Kapoor","doi":"10.1007/s12247-025-09985-4","DOIUrl":"10.1007/s12247-025-09985-4","url":null,"abstract":"<div><h3>Purpose</h3><p>Posaconazole (POS) is widely used as an antifungal agent effective against Candida infections. Because of its very low water and high fat solubility, it falls under the Biopharmaceutics Classification System (BCS) Class II. It showed considerable differences in absorption rates among individuals when administered orally. To overcome these obstacles, the current research concentrates on creating a solid self nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of POS to enhance its dissolution rate and bioavailability.</p><h3>Methods</h3><p>The choice of formulation components, Capmul MCM C8 as an oil, Tween 20 as a surfactant, and Acrysol K140 as a co-surfactant depended on their ability to solubilize POS and their capacity to form emulsions. Ternary phase diagrams were drawn to pinpoint and delineate the micro-emulsification region. The D-optimal mixture design was employed to facilitate the selection of the most optimized formulation by evaluating vital product characteristics including globule size, zeta potential, transparency percentage as well as emulsification efficiency. The optimized liquid SNEDDS (L-SNEDDS) was then converted into a solid state by employing Neusilin<sup>®</sup> US2 as a porous carrier, improving the product’s stability and handling ease. The prepared formulation was further evaluated by in vitro and in vivo study.</p><h3>Results</h3><p>Examination of the S-SNEDDS structure through scanning electron microscopy showed spherical, granular particles, suggesting favourable flow characteristics. Dissolution tests conducted in vitro revealed that the rate of POS release from the S-SNEDDS was superior to that of unprocessed drug and marketed formulation. In vivo bioavailability study showed 2.27 and 1.96 fold higher bioavailability as compared to pure drug and marketed formulation respectively.</p><h3>Conclusion</h3><p>Present study revealed that the ability to self-emulsify was preserved when the L-SNEDDS was solidified. Further it demonstrated enhancement in dissolution and bioavailability of POS which depicted use of developed POS loaded S-SNEDDS for successful oral administration.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancement of Solubility and Bioavailability of Bezafibrate Based on Hydrotropy and Solid Dispersion Technique
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-14 DOI: 10.1007/s12247-025-09984-5
Jie Liu, Qingyue Liu, Zhi Zhang, Wenzhi Yang, Haiying Li

Purpose

Bezafibrate (BZF), a fibrates lipid-lowering drug, is primarily used in clinical practice for hyperlipidemia with significantly elevated triglycerides (TG). Its effect on reducing TG is more pronounced than that of statins, compensating for the shortcomings of statin medications. However, BZF is a BCS class II drug due to its low solubility in water and its poor oral bioavailability. To enhance the solubility and bioavailability of BZF, a co-amorphous complex comprising BZF and a hydrotrope was prepared.

Methods

Arginine (Arg) was selected as a hydrotrope for BZF. The BZF-Arg co-amorphous complex was prepared by the freeze-drying method and characterized by Fourier transform infrared spectroscopy (FT-IR), X-ray powder diffraction (XRPD), and differential scanning calorimetry (DSC). Moreover, the complex was evaluated by stability test, in vitro release experiment and pharmacokinetic study.

Results

The characterization results demonstrated that the formation of hydrogen bonds between BZF and Arg, and the crystalline state of the drug was transformed into the amorphous state in the BZF-Arg complex. Moreover, the complex exhibited good stability and better release in vitro. The pharmacokinetic study revealed that the peak concentration (Cmax) and the area under the curve (AUC0→36) of the BZF-Arg complex were significantly improved compared to those of the BZF suspension, following the relative bioavailability of 255%.

Conclusion

BZF-Arg co-amorphous complex prepared by the combination of hydrotropy and solid dispersion technique provides a promising strategy for enhancing the solubility and bioavailability of BZF.

Graphical Abstract

{"title":"Enhancement of Solubility and Bioavailability of Bezafibrate Based on Hydrotropy and Solid Dispersion Technique","authors":"Jie Liu,&nbsp;Qingyue Liu,&nbsp;Zhi Zhang,&nbsp;Wenzhi Yang,&nbsp;Haiying Li","doi":"10.1007/s12247-025-09984-5","DOIUrl":"10.1007/s12247-025-09984-5","url":null,"abstract":"<div><h3>Purpose</h3><p>Bezafibrate (BZF), a fibrates lipid-lowering drug, is primarily used in clinical practice for hyperlipidemia with significantly elevated triglycerides (TG). Its effect on reducing TG is more pronounced than that of statins, compensating for the shortcomings of statin medications. However, BZF is a BCS class II drug due to its low solubility in water and its poor oral bioavailability. To enhance the solubility and bioavailability of BZF, a co-amorphous complex comprising BZF and a hydrotrope was prepared.</p><h3>Methods</h3><p>Arginine (Arg) was selected as a hydrotrope for BZF. The BZF-Arg co-amorphous complex was prepared by the freeze-drying method and characterized by Fourier transform infrared spectroscopy (FT-IR), X-ray powder diffraction (XRPD), and differential scanning calorimetry (DSC). Moreover, the complex was evaluated by stability test, in vitro release experiment and pharmacokinetic study.</p><h3>Results</h3><p>The characterization results demonstrated that the formation of hydrogen bonds between BZF and Arg, and the crystalline state of the drug was transformed into the amorphous state in the BZF-Arg complex. Moreover, the complex exhibited good stability and better release in vitro. The pharmacokinetic study revealed that the peak concentration (C<sub>max</sub>) and the area under the curve (AUC<sub>0→36</sub>) of the BZF-Arg complex were significantly improved compared to those of the BZF suspension, following the relative bioavailability of 255%.</p><h3>Conclusion</h3><p>BZF-Arg co-amorphous complex prepared by the combination of hydrotropy and solid dispersion technique provides a promising strategy for enhancing the solubility and bioavailability of BZF.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polymorphic Stability and Enhanced Drug Release of Dabigatran Etexilate Mesylate in Mesoporous Silica-Based Liquisolid Systems- Formulation and In Vitro Evaluation
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-14 DOI: 10.1007/s12247-025-09986-3
Sayani Bhattacharyya, Manish Gurung, Kogileshwari Sivakumar

Purpose

Dabigatran etexilate mesylate, a BCS Class II drug used in the prevention of deep vein thrombosis and brain stroke, exhibits poor bioavailability and polymorphic tendencies. To address these challenges, this study focuses on formulating liquisolid compact tablets of dabigatran etexilate mesylate.

Methods

The liquisolid technique uses propylene glycol as a non-volatile solvent, with Neusilin US2 and microcrystalline cellulose (MCC) serving as carrier materials, and Syloid 244FP employed as a coating agent. The formulation was optimized through a central composite design to evaluate the effects of excipient ratio and super disintegrant concentration on flow properties and dissolution behavior.

Result

The optimized liquisolid formulation demonstrated enhanced solubility and drug release, with 91.07% cumulative drug release compared to directly compressible tablets. Differential scanning calorimetry (DSC) measurements and powder X-ray diffraction (PXRD) analyses confirmed the molecular dispersion of the drug and the preservation of its crystalline Form III. Stability studies indicated no significant changes in dissolution profiles or physical properties over three months.

Conclusion

This study demonstrates the effectiveness of the liquisolid technique in enhancing the solubility, dissolution rate, and stability of dabigatran etexilate mesylate while also preventing polymorphic transformation.

{"title":"Polymorphic Stability and Enhanced Drug Release of Dabigatran Etexilate Mesylate in Mesoporous Silica-Based Liquisolid Systems- Formulation and In Vitro Evaluation","authors":"Sayani Bhattacharyya,&nbsp;Manish Gurung,&nbsp;Kogileshwari Sivakumar","doi":"10.1007/s12247-025-09986-3","DOIUrl":"10.1007/s12247-025-09986-3","url":null,"abstract":"<div><h3>Purpose</h3><p>Dabigatran etexilate mesylate, a BCS Class II drug used in the prevention of deep vein thrombosis and brain stroke, exhibits poor bioavailability and polymorphic tendencies. To address these challenges, this study focuses on formulating liquisolid compact tablets of dabigatran etexilate mesylate.</p><h3>Methods</h3><p>The liquisolid technique uses propylene glycol as a non-volatile solvent, with Neusilin US2 and microcrystalline cellulose (MCC) serving as carrier materials, and Syloid 244FP employed as a coating agent. The formulation was optimized through a central composite design to evaluate the effects of excipient ratio and super disintegrant concentration on flow properties and dissolution behavior.</p><h3>Result</h3><p>The optimized liquisolid formulation demonstrated enhanced solubility and drug release, with 91.07% cumulative drug release compared to directly compressible tablets. Differential scanning calorimetry (DSC) measurements and powder X-ray diffraction (PXRD) analyses confirmed the molecular dispersion of the drug and the preservation of its crystalline Form III. Stability studies indicated no significant changes in dissolution profiles or physical properties over three months.</p><h3>Conclusion</h3><p>This study demonstrates the effectiveness of the liquisolid technique in enhancing the solubility, dissolution rate, and stability of dabigatran etexilate mesylate while also preventing polymorphic transformation.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
QbD-Based Optimization of Fast Dissolving Sublingual Tablets of Valsartan
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-11 DOI: 10.1007/s12247-025-09983-6
Ishan Dubey, Deepak Joshi, Amrut Walvekar, Pankaj Kumar Pandey, Pallavi Singh Chouhan

Background

Valsartan, an angiotensin II receptor blocker, is commonly prescribed for managing hypertension and heart failure. However, its poor aqueous solubility and extensive first-pass metabolism limit its bioavailability, necessitating the development of an alternative delivery system. This study aimed to optimize the formulation of a sublingual fast-dissolving tablet of Valsartan to enhance drug dissolution and absorption for rapid therapeutic action.

Methods

A Box-Behnken Design (BBD) was employed to evaluate the influence of three super disintegrants—Sodium Starch Glycolate (SSG), Crospovidone (CP), and Croscarmellose Sodium (CCS)—on critical formulation parameters: disintegration time (DT) and cumulative drug release (CDR%). The optimized formulation (OVSF-18) was selected based on desirability criteria and further subjected to in vitro dissolution studies, release kinetics, and stability assessment to ensure formulation robustness.

Results

The response surface analysis revealed that SSG had the most significant impact on reducing DT, followed by CP, while CCS contributed moderately. The optimized formulation (OVSF-18) exhibited a disintegration time of 33.33 s and achieved 92.33% cumulative drug release within 15 min, demonstrating superior performance compared to marketed tablets. Stability studies confirmed the formulation’s physicochemical integrity over the test period.

Conclusion

The optimized sublingual Valsartan significantly enhances drug dissolution and absorption by circumventing first-pass metabolism, offering a promising alternative to conventional oral formulations. Its rapid onset of action and improved bioavailability make it particularly suitable for hypertensive emergencies and heart failure management. This study establishes a foundation for further clinical evaluation and potential commercialization of sublingual Valsartan tablets as an effective therapeutic option.

{"title":"QbD-Based Optimization of Fast Dissolving Sublingual Tablets of Valsartan","authors":"Ishan Dubey,&nbsp;Deepak Joshi,&nbsp;Amrut Walvekar,&nbsp;Pankaj Kumar Pandey,&nbsp;Pallavi Singh Chouhan","doi":"10.1007/s12247-025-09983-6","DOIUrl":"10.1007/s12247-025-09983-6","url":null,"abstract":"<div><h3>Background</h3><p>Valsartan, an angiotensin II receptor blocker, is commonly prescribed for managing hypertension and heart failure. However, its poor aqueous solubility and extensive first-pass metabolism limit its bioavailability, necessitating the development of an alternative delivery system. This study aimed to optimize the formulation of a sublingual fast-dissolving tablet of Valsartan to enhance drug dissolution and absorption for rapid therapeutic action.</p><h3>Methods</h3><p>A Box-Behnken Design (BBD) was employed to evaluate the influence of three super disintegrants—Sodium Starch Glycolate (SSG), Crospovidone (CP), and Croscarmellose Sodium (CCS)—on critical formulation parameters: disintegration time (DT) and cumulative drug release (CDR%). The optimized formulation (OVSF-18) was selected based on desirability criteria and further subjected to in vitro dissolution studies, release kinetics, and stability assessment to ensure formulation robustness.</p><h3>Results</h3><p>The response surface analysis revealed that SSG had the most significant impact on reducing DT, followed by CP, while CCS contributed moderately. The optimized formulation (OVSF-18) exhibited a disintegration time of 33.33 s and achieved 92.33% cumulative drug release within 15 min, demonstrating superior performance compared to marketed tablets. Stability studies confirmed the formulation’s physicochemical integrity over the test period.</p><h3>Conclusion</h3><p>The optimized sublingual Valsartan significantly enhances drug dissolution and absorption by circumventing first-pass metabolism, offering a promising alternative to conventional oral formulations. Its rapid onset of action and improved bioavailability make it particularly suitable for hypertensive emergencies and heart failure management. This study establishes a foundation for further clinical evaluation and potential commercialization of sublingual Valsartan tablets as an effective therapeutic option.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143818220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baicalein-Loaded Aspasomal Formulations: Development, Characterization and Evaluation of Antioxidant and Anti-Inflammatory Effects
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-08 DOI: 10.1007/s12247-025-09979-2
Fatih Hozan, Esma Nur Uslu, Gökçe Şeker Karatoprak, Çiğdem Yücel
<div><h3>Background</h3><p>Aspasomes are bilayer vesicular systems developed with ascorbyl palmitate (AP), the ester form of ascorbic acid. Baicalein is a flavonoid structure, a powerful antioxidant, can neutralize free radicals, helps protect cells from oxidative damage, has an anti-inflammatory effect by suppressing the release of inflammatory mediators and relieves related symptoms, but its poor solubility and stability play a critical role in limiting its activity.</p><h3>Purpose</h3><p>To relieve the above-mentioned problems and to increase the effectiveness of baicalein, we prepared aspasomal formulations.</p><h3>Methods</h3><p>We produced five different baicalein-loaded aspasomal formulations prepared with different components and characterized in terms of particle size (PS), polydispersity index (PDI), zeta potential (ZP), scanning electron microscopy (SEM), drug encapsulation efficiency (EE%) and drug release. The best formulation was selected and used to prepare the aspasomal gel by using Carbopol 980 as a gelling agent at a ratio of 1:1 (v/v). The cytotoxicity of the aspasomes and different baicalein solutions on the RAW 264.7 cell line by using 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. In the stability studies, changes in characterization parameters and baicalein content in two different conditions over 3 months were monitored. The cell permeation study was performed using RAW 264.7 murine macrophages cell with aspasomes in suspension and gel form and the amounts of penetrated baicalein were measured. At the end of the permeation study, the antioxidant and anti-inflammatory effect were determined. Within the scope of antioxidant activity studies, 1,1-diphenyl-2-picrylhydrazyl (DPPH●) and 2,2’-azino-bis (3-ethylbenzathiazoline-6-sulfonic acid) (ABTS+●) radical scavenging effects were determined. Nitric oxide (NO), tumor necrosis factor-alpha (TNF-α) and prostaglandin 2 (PGE2) levels released into the intracellular and nutrient medium were determined in the anti-inflammatory effect determination.</p><h3>Results</h3><p>Based on results, the selected optimum aspasomal formulation (F2 coded) showed PS of 425 ± 1.00 nm, ZP of -38.1 ± 1.31, PDI of 0.207 ± 0.015, EE of 40 ± 1.02% and drug release of 85 ± 0.95%. The baicalein content of aspasomes were physically stable, and it was not observed decrease significantly during 3 months of storage at 4ºC. The gel formulation stored at 4 °C showed better physicochemical properties compared to 25 °C ± 65% relative humidity and did not show a significant change at the end of 3 months. Although the pH of aspasomal gel decreased slightly over time and with increasing temperature, it was still in the appropriate range for skin pH. The cell permeation assay results showed effective baicalein permeation rate. The antioxidant and anti-inflammatory effects obtained were significant, although low, compared to the positive control indomethacin.</p><h3>Conclusion</h3><p>Baicalein e
背景天体是由抗坏血酸的酯形式--棕榈酸抗坏血酸酯(AP)发育而成的双层囊泡系统。黄芩素是一种黄酮类结构,是一种强效抗氧化剂,能中和自由基,帮助保护细胞免受氧化损伤,并通过抑制炎症介质的释放和缓解相关症状而具有抗炎作用,但其溶解性和稳定性差对其活性起着关键的限制作用。为了解决上述问题,提高黄芩苷的疗效,我们制备了黄芩苷aspasomal制剂。通过使用 Carbopol 980 作为胶凝剂,以 1:1 的比例(v/v)制备aspasomal 凝胶,选出了最佳配方。使用 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑(MTT)测试了阿司巴姆和不同黄芩苷溶液对 RAW 264.7 细胞系的细胞毒性。在稳定性研究中,监测了 3 个月内两种不同条件下表征参数和黄芩苷含量的变化。细胞渗透研究是使用 RAW 264.7 小鼠巨噬细胞与悬浮和凝胶形式的天冬酰胺进行的,并测量了黄芩素的渗透量。渗透研究结束后,测定了抗氧化和抗炎效果。在抗氧化活性研究范围内,测定了 1,1-二苯基-2-苦基肼(DPPH●)和 2,2'-偶氮-双(3-乙基苯并噻唑啉-6-磺酸)(ABTS+●)自由基清除效果。一氧化氮(NO)、肿瘤坏死因子-α(TNF-α)和前列腺素 2(PGE2)在细胞内和营养介质中的释放水平也被用于抗炎效果的测定。结果根据结果,所选的最佳天冬酰胺囊制剂(F2 编码)的 PS 值为 425 ± 1.00 nm,ZP 值为 -38.1 ± 1.31,PDI 值为 0.207 ± 0.015,EE 值为 40 ± 1.02%,药物释放率为 85 ± 0.95%。黄芩苷含量在 4ºC 储存 3 个月后没有明显下降。与 25 °C ± 65% 的相对湿度相比,在 4 °C 下储存的凝胶制剂显示出更好的理化特性,并且在 3 个月结束时未显示出明显变化。虽然随着时间的推移和温度的升高,aspasomal 凝胶的 pH 值略有下降,但仍处于皮肤 pH 值的适当范围内。细胞渗透试验结果表明黄芩苷的渗透率很高。与阳性对照吲哚美辛相比,黄芩苷的抗氧化和抗炎作用虽然较低,但效果显著。
{"title":"Baicalein-Loaded Aspasomal Formulations: Development, Characterization and Evaluation of Antioxidant and Anti-Inflammatory Effects","authors":"Fatih Hozan,&nbsp;Esma Nur Uslu,&nbsp;Gökçe Şeker Karatoprak,&nbsp;Çiğdem Yücel","doi":"10.1007/s12247-025-09979-2","DOIUrl":"10.1007/s12247-025-09979-2","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Aspasomes are bilayer vesicular systems developed with ascorbyl palmitate (AP), the ester form of ascorbic acid. Baicalein is a flavonoid structure, a powerful antioxidant, can neutralize free radicals, helps protect cells from oxidative damage, has an anti-inflammatory effect by suppressing the release of inflammatory mediators and relieves related symptoms, but its poor solubility and stability play a critical role in limiting its activity.&lt;/p&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;p&gt;To relieve the above-mentioned problems and to increase the effectiveness of baicalein, we prepared aspasomal formulations.&lt;/p&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;We produced five different baicalein-loaded aspasomal formulations prepared with different components and characterized in terms of particle size (PS), polydispersity index (PDI), zeta potential (ZP), scanning electron microscopy (SEM), drug encapsulation efficiency (EE%) and drug release. The best formulation was selected and used to prepare the aspasomal gel by using Carbopol 980 as a gelling agent at a ratio of 1:1 (v/v). The cytotoxicity of the aspasomes and different baicalein solutions on the RAW 264.7 cell line by using 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. In the stability studies, changes in characterization parameters and baicalein content in two different conditions over 3 months were monitored. The cell permeation study was performed using RAW 264.7 murine macrophages cell with aspasomes in suspension and gel form and the amounts of penetrated baicalein were measured. At the end of the permeation study, the antioxidant and anti-inflammatory effect were determined. Within the scope of antioxidant activity studies, 1,1-diphenyl-2-picrylhydrazyl (DPPH●) and 2,2’-azino-bis (3-ethylbenzathiazoline-6-sulfonic acid) (ABTS+●) radical scavenging effects were determined. Nitric oxide (NO), tumor necrosis factor-alpha (TNF-α) and prostaglandin 2 (PGE2) levels released into the intracellular and nutrient medium were determined in the anti-inflammatory effect determination.&lt;/p&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Based on results, the selected optimum aspasomal formulation (F2 coded) showed PS of 425 ± 1.00 nm, ZP of -38.1 ± 1.31, PDI of 0.207 ± 0.015, EE of 40 ± 1.02% and drug release of 85 ± 0.95%. The baicalein content of aspasomes were physically stable, and it was not observed decrease significantly during 3 months of storage at 4ºC. The gel formulation stored at 4 °C showed better physicochemical properties compared to 25 °C ± 65% relative humidity and did not show a significant change at the end of 3 months. Although the pH of aspasomal gel decreased slightly over time and with increasing temperature, it was still in the appropriate range for skin pH. The cell permeation assay results showed effective baicalein permeation rate. The antioxidant and anti-inflammatory effects obtained were significant, although low, compared to the positive control indomethacin.&lt;/p&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Baicalein e","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12247-025-09979-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Equipment Material and Surface Finish on the Flowability of dry Cohesive Powders – an Important Consideration in Calibration of Discrete Element Models
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-08 DOI: 10.1007/s12247-025-09950-1
Ankita Sharma, Jayanta Chakraborty, Anurag Tripathi, Jitendra Kumar, Maitraye Sen, William Ketterhagen

Discrete Element Method (DEM) simulations of cohesive particles are of great importance in understanding powder flows in processing equipment. Calibration of the particle–particle or particle–wall interaction parameters is important, and although there are many studies on DEM simulations of cohesive powders, most of them do not differentiate between particle–particle cohesive and particle–wall adhesive forces. In this work, a bench-top experimental setup was designed to demonstrate the effect of particle–wall adhesive forces. A simulation-based sensitivity analysis was also performed using a commercial scale tablet press feeder (TPF) and hopper screw feeder (HSF), by independently varying the particle–particle and particle–wall cohesive energy density values to illustrate their effect on powder flowability. Both the feeders experienced blockages for highly cohesive particles whose cohesive energy density exceeds 80 kJ/m3 in case of TPF and 110 kJ/m3 for HSF. The occurrence of such blockages was eliminated by reducing the particle–wall adhesion to 30 kJ/m3 in case of TPF and 50 kJ/m3 for HSF while keeping the particle–particle cohesion at the same high value. Thus, this work demonstrates that the particle–particle cohesion and particle wall adhesion should be considered as separate entities and must be calibrated separately in DEM so that the materials interaction effects of both powder and equipment can be captured adequately.

{"title":"Impact of Equipment Material and Surface Finish on the Flowability of dry Cohesive Powders – an Important Consideration in Calibration of Discrete Element Models","authors":"Ankita Sharma,&nbsp;Jayanta Chakraborty,&nbsp;Anurag Tripathi,&nbsp;Jitendra Kumar,&nbsp;Maitraye Sen,&nbsp;William Ketterhagen","doi":"10.1007/s12247-025-09950-1","DOIUrl":"10.1007/s12247-025-09950-1","url":null,"abstract":"<div><p>Discrete Element Method (DEM) simulations of cohesive particles are of great importance in understanding powder flows in processing equipment. Calibration of the particle–particle or particle–wall interaction parameters is important, and although there are many studies on DEM simulations of cohesive powders, most of them do not differentiate between particle–particle cohesive and particle–wall adhesive forces. In this work, a bench-top experimental setup was designed to demonstrate the effect of particle–wall adhesive forces. A simulation-based sensitivity analysis was also performed using a commercial scale tablet press feeder (TPF) and hopper screw feeder (HSF), by independently varying the particle–particle and particle–wall cohesive energy density values to illustrate their effect on powder flowability. Both the feeders experienced blockages for highly cohesive particles whose cohesive energy density exceeds 80 kJ/m<sup>3</sup> in case of TPF and 110 kJ/m<sup>3</sup> for HSF. The occurrence of such blockages was eliminated by reducing the particle–wall adhesion to 30 kJ/m<sup>3</sup> in case of TPF and 50 kJ/m<sup>3</sup> for HSF while keeping the particle–particle cohesion at the same high value. Thus, this work demonstrates that the particle–particle cohesion and particle wall adhesion should be considered as separate entities and must be calibrated separately in DEM so that the materials interaction effects of both powder and equipment can be captured adequately.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143801239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Innovation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1